获得性再生障碍性贫血（aplastic anemia, AA）是严重威胁生命的疾病，其发病与Th17数量增加及Treg数量减少（Th17/Treg平衡失调）密切相关。课题组在前期临床及体外研究中证实，靶向调控Th17/Treg平衡，是治疗AA的有效手段。既往有研究表明，低氧诱导因子HIF-1α可诱导Th17分化，调控Th17/Treg平衡，其作用依赖STAT3信号通路。红景天苷具有抗缺氧、抗炎等作用，临床应用红景天治疗AA获得良好疗效，但作用机制不明。既往研究发现，在肺损伤、心梗等缺血缺氧性疾病中，红景天可通过抑制HIF-1α发挥作用。由此我们推测，红景天苷可能通过调控STAT3/HIF-1α/RORγt信号通路，抑制Th17分化，进而纠正Th17/Treg失衡。本研究拟在前期工作基础上进一步研究红景天苷治疗AA的分子通路机制，为红景天苷治疗AA提供理论依据。

Acquired aplastic anemia (aplastic anemia, AA) is a seriously life-threatening disease, and its incidence is closely linked to an increase in the number of TH17 cells and a decrease in the number of T regulatory cells (Th17/Treg imbalance). In the early clinical and in vitro studies, our group confirmed that target regulating Th17/treg balance was an effective method for the treatment of AA.Previous studies have shown that hypoxic-induced factor hif-1α can induce Th17 cells differentiation, regulate Th17/Treg equilibrium, and its effect depends on STAT3 signaling pathway. Rhodiola has anti-hypoxia, anti-inflammatory and other effects. Clinical application of Rhodiola to treat AA has obtained good results, but the mechanism of its action is unknown.Previous studies have found that Rhodiola can play a role by inhibiting hif-1α in ischemic and hypoxic diseases such as lung injury and myocardial infarction. So we speculate that Rhodiola may correct the th17/treg imbalance by regulating the stat3/hif-1α/rorγt signaling pathway and inhibiting TH17 differentiation.On the basis of the previous work, this study intends to further study the molecular pathway mechanism of Rhodiola in the treatment of AA, and provide theoretical basis for the treatment AA of Rhodiola.